Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

The vaccine contains chemically inactivated (killed) poliovirus particles of three serotypes. After injection, the immune system recognises these antigens, activates T‑cells and stimulates B‑cells to produce neutralising antibodies. These antibodies provide protective immunity without causing disease.

The specific dose and schedule are determined by the prescribing healthcare professional according to national immunisation guidelines. Typically, the vaccine is given as a series of intramuscular injections, but the exact volume and timing are set by the clinician based on age and risk factors.

Safety data for use of Imovax Polio during pregnancy are limited. Healthcare providers should weigh the potential benefits against any unknown risks. The vaccine is not known to be excreted in breast milk, but a clinician’s advice is recommended before administration to pregnant or nursing individuals.

To place an order, submit an enquiry on the Imovax Polio product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and required import documentation.

Imovax Polio is an inactivated (killed) vaccine, whereas the oral polio vaccine (OPV) contains live attenuated virus. IPV, like Imovax, does not carry a risk of vaccine‑derived poliovirus infection and is preferred in settings where OPV‑related outbreaks are a concern. Both provide immunity, but IPV requires injection and induces primarily humoral immunity.

Imovax Polio must be stored refrigerated at 2 °C to 8 °C. It should be kept in the original packaging to protect from light, must not be frozen, and should not be shaken. Prior to administration, allow the vial to reach room temperature if required, and inspect for particulate matter.

The vaccine is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm or the anterolateral thigh in infants. The injection site should be cleaned with an appropriate antiseptic, and the dose is delivered using a sterile needle and syringe.

While most reactions are mild, serious adverse events can include anaphylaxis, severe allergic reactions to vaccine components, seizures, Guillain‑Barré syndrome, and sudden hypotension. Any signs of difficulty breathing, swelling of the face or throat, or a rapid drop in blood pressure after vaccination require immediate medical attention.

Individuals with a known severe allergy to any component of the vaccine, such as gelatin or neomycin, should not receive Imovax Polio. Persons who have experienced a previous severe reaction to an inactivated poliovirus vaccine should also avoid it. In all other cases, the vaccine can be administered after clinical evaluation.